1. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Issue 10192 (6th July 2019) Authors: Pratley, Richard; Amod, Aslam; Hoff, Søren Tetens; Kadowaki, Takashi; Lingvay, Ildiko; Nauck, Michael; Pedersen, Karen Boje; Saugstrup, Trine; Meier, Juris J Journal: Lancet Issue: Volume 394:Issue 10192(2019) Page Start: 39 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FP482EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER. (13th June 2019) Authors: Perkovic, Vlado; Bain, Stephen; Bakris, George; Buse, John; Gondolf, Theis; Idorn, Thomas; Lausvig, Nanna; Mahaffey, Kenneth; Marso, Steven; Nauck, Michael; Pratley, Richard; Rossing, Peter; Zinman, Bernard; Mann, Johannes Journal: Nephrology dialysis transplantation Issue: Volume 34(2019)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SaO010EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES – A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS. (13th June 2019) Authors: Perkovic, Vlado; Bain, Stephen; Bakris, George; Buse, John; Idorn, Thomas; Mahaffey, Kenneth; Marso, Steven; Nauck, Michael; Pratley, Richard; Rasmussen, Søren; Rossing, Peter; Tornoe, Karen; Zinman, Bernard; Mann, Johannes Journal: Nephrology dialysis transplantation Issue: Volume 34(2019)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Issue 7 (July 2019) Authors: Mosenzon, Ofri; Blicher, Thalia Marie; Rosenlund, Signe; Eriksson, Jan W; Heller, Simon; Hels, Ole Holm; Pratley, Richard; Sathyapalan, Thozhukat; Desouza, Cyrus Journal: Lancet Issue: Volume 7:Issue 7(2019) Page Start: 515 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Kidney outcomes using a sustained ≥40% decline in eGFR: A meta‐analysis of SGLT2 inhibitor trials. Issue 8 (15th June 2021) Authors: Cherney, David Z. I.; Dagogo‐Jack, Samuel; McGuire, Darren K.; Cosentino, Francesco; Pratley, Richard; Shih, Weichung J.; Frederich, Robert; Maldonado, Mario; Liu, Jie; Wang, Shuai; Cannon, Christopher P. Journal: Clinical cardiology Issue: Volume 44:Issue 8(2021) Page Start: 1139 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Issue 4 (April 2021) Authors: von Herrath, Matthias; Bain, Stephen C; Bode, Bruce; Clausen, Jesper Ole; Coppieters, Ken; Gaysina, Leylya; Gumprecht, Janusz; Hansen, Troels Krarup; Mathieu, Chantal; Morales, Cristobal; Mosenzon, Ofri; Segel, Stine; Tsoukas, George; Pieber, Thomas R; Ludvik, Bernhard; Prager, Rudolf; Paulweber,... Journal: Lancet Issue: Volume 9:Issue 4(2021) Page Start: 212 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Issue 8 (22nd February 2022) Authors: Lam, Carolyn S.P.; Ramasundarahettige, Chinthanie; Branch, Kelley R.H.; Sattar, Naveed; Rosenstock, Julio; Pratley, Richard; Del Prato, Stefano; Lopes, Renato D.; Niemoeller, Elisabeth; Khurmi, Nardev S.; Baek, Seungjae; Gerstein, Hertzel C. Journal: Circulation Issue: Volume 145:Issue 8(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Dietary intake on days with and without hypoglycemia in youth with type 1 diabetes: The Flexible Lifestyle Empowering Change trial. Issue 8 (5th October 2020) Authors: Igudesman, Daria; Crandell, Jamie; Zhong, Victor W.; Cristello Sarteau, Angelica; Kahkoska, Anna R.; Corbin, Karen; Pratley, Richard; Kosorok, Michael R.; Maahs, David M.; Mayer‐Davis, Elizabeth J. Journal: Pediatric diabetes Issue: Volume 21:Issue 8(2020) Page Start: 1475 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Design and baseline characteristics of the AMPLITUDE‐O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon‐like peptide‐1 receptor agonist. Issue 2 (22nd October 2020) Authors: Gerstein, Hertzel C.; Branch, Kelley; Heenan, Laura; Del Prato, Stefano; Khurmi, Nardev S.; Lam, Carolyn S. P.; Pratley, Richard; Rosenstock, Julio; Sattar, Naveed Journal: Diabetes, obesity & metabolism Issue: Volume 23:Issue 2(2021) Page Start: 318 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Associations of Diet With the Intestinal Microbiota and Short-Chain Fatty Acids Among Young Adults With Type 1 Diabetes: The ACT1ON Ancillary Gut Microbiome Pilot Study. (14th June 2022) Authors: Igudesman, Daria; Crandell, Jamie; Corbin, Karen; Hooper, Julie; Thomas, Joan; Bulik, Cynthia; Carroll, Ian; Pence, Brian; Pratley, Richard; Kosorok, Michael; Maahs, David; Mayer-Davis, Elizabethd Journal: Current developments in nutrition Issue: Volume 6(2022)Supplement 1 Page Start: 1012 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗